Beyond overall response rates, a critical area of excitement for new ADCs in lung cancer is their potential to treat brain metastases. Early data showing hints of intracranial efficacy is a significant point of interest, as this addresses a common and difficult-to-treat site of disease progression, offering a potential advantage over other therapies.

The future of advanced prostate cancer treatment may involve combining ADCs with bispecific T-cell engagers. This strategy could use ADCs for a short duration to deliver a potent hit, followed by immunotherapy to achieve durable remission, potentially reducing toxicity and enabling earlier use.

After standard immunotherapy biomarkers like PD-L1 and TMB proved ineffective in SCLC, the field shifted to a more direct approach. Novel therapies like the bispecific antibody tarlatumab target surface proteins such as DLL3, physically bridging immune cells to cancer cells without relying on predictive biomarkers.

The future of medicine isn't about finding a single 'best' modality like CAR-T or gene therapy. Instead, it's about strategic convergence, choosing the right tool—be it a bispecific, ADC, or another biologic—based on the patient's specific disease stage and urgency of treatment.

Rather than moving through distinct lines of therapy, a future strategy could involve an "ADC switch." When a patient progresses on an ADC-IO combination, the IO backbone would remain while the ADC is swapped for one with a different, non-cross-resistant mechanism, adapting the treatment in real-time.

While TROP2-ADCs are currently approved for later-line lung cancer treatment, active clinical trials are already evaluating them as a potential replacement for traditional chemotherapy in the first-line setting. This represents a significant strategic ambition to shift the entire treatment paradigm for newly diagnosed patients with both non-small cell and small cell lung cancer.

While immunotherapy was a massive leap forward, Dr. Saav Solanki states the next innovation frontier is combining it with newer modalities. Antibody-drug conjugates (ADCs) and T-cell engagers are being used to recruit the immune system into the tumor microenvironment, helping patients who don't respond to current immunotherapies.

The long-standing platinum doublet backbone for frontline SCLC may soon be challenged. The high efficacy of novel agents like antibody-drug conjugates and bispecific antibodies in later lines is prompting trials that consider moving them into the first-line setting, a strategy previously considered "unthinkable."

As multiple effective Antibody-Drug Conjugates (ADCs) become available, the primary clinical challenge is no longer *if* they work, but *how* to use them best. Key unanswered questions involve optimal sequencing, dosing for treatment versus maintenance, and overall length of therapy, mirroring issues already seen in breast cancer.